Well, of course not. If you borrow a trillion dollars to build a 1¢ aspirin machine to compete with $1 generic aspirin, you are strongly incentivized to sell your aspirin for 99¢. We don’t see productivity gains, because approximately all of the gain is captured as revenue for AI companies.

It’s weird that this has to be spelled out for so many engineers and economists, but to be very clear: OpenAI et al wants your token spend to go to one-minus-epsilon of what you previously spent on payroll, and wants your productivity to go to one-plus-epsilon of what it previously was. If you want 10x productivity, spend 9.9x more on tokens.

They are in the business of enclosure and rent extraction, and any innovation that comes out of their research and development - regardless of how real an innovation it is - will be completely contained and bent totally towards that business. Any leakage of the innovation that you experience as a productivity boost is literally felt as lost profits by them.